The Indian Pharmacopoeia Commission (IPC), under the Ministry of Health and Family Welfare, launched seven Indian Pharmacopoeia Nitrosamine Impurities Reference Standards for the first time, at a meeting titled "IP 2026: Perspectives, Suggestions and Way Forward" held with the Central Drugs Laboratory and Central Cosmetics Laboratory in Kolkata, West Bengal. The seven standards are NDMA, NDEA, NEIPA, NDBA, NMPA, NDIPA and NMBA. Nitrosamines are genotoxic and carcinogenic compounds that can arise unintentionally during manufacturing, storage or packaging. The standards will support analytical method validation, quality assurance and self-reliance in critical reference materials.
GK ByteIPC launched seven Nitrosamine Impurities Reference Standards for the first time, at Kolkata, West BengalThe seven standards: NDMA, NDEA, NEIPA, NDBA, NMPA, NDIPA and NMBAIPC functions under the Ministry of Health and Family WelfareNitrosamines are genotoxic and carcinogenic impurities that can form during manufacturing, storage or packaging
The Ministry of Health and Family Welfare has prohibited the manufacture, sale and distribution of fixed-dose combinations of the antihistamine Chlorpheniramine Maleate and the decongestant Phenylephrine Hydrochloride for children below four years, covering syrups and drops alike. The order invokes Section 26A of the Drugs and Cosmetics Act, 1940, which empowers the Centre to restrict a drug in the public interest, and follows assessment by the Drugs Technical Advisory Board (DTAB). Packs, labels, inserts and promotional material must now carry the warning that the FDC is not for under-fours. It widens a 15 April 2025 notification and follows June 2026's ban on 16 irrational FDCs.
GK ByteLegal power used: Section 26A of the Drugs and Cosmetics Act, 1940 — restriction of a drug in the public interest.Age cut-off is children below four years; applies to all such formulations including syrups and drops.Advised by an Expert Committee and the Drugs Technical Advisory Board (DTAB); CDSCO is the national drug regulator.Expands a 15 April 2025 notification; follows the June 2026 ban on 16 irrational fixed-dose combinations.
Delhi has recorded 1,777 confirmed swine flu cases, with hospitals reporting a spurt in illness across all age groups over the past two weeks. Swine influenza is a respiratory disease of pigs caused by type A influenza viruses, the most common subtypes being H1N1, H1N2 and H3N2. The H1N1 strain caused the 2009 pandemic, and H1N1, H3N2 and some Influenza B strains have circulated worldwide since. It spreads mainly through coughing and sneezing, or by touching a contaminated surface. Treatment is largely supportive — antibiotics do not work on viruses — while the antiviral oseltamivir, taken early, reduces severity.
GK ByteDelhi recorded 1,777 confirmed swine flu cases, with a surge across all age groups.Swine influenza is caused by type A influenza viruses; common subtypes are H1N1, H1N2 and H3N2.H1N1 caused the 2009 influenza pandemic.Oseltamivir is the antiviral used; antibiotics are ineffective against viral infection.
Researchers at the Institute of Advanced Study in Science and Technology (IASST), Guwahati, led by Dr. Asis Bala, along with Dr. K.P. Bhabak of IIT Guwahati, announced a "smart" cancer drug named RK-251 on 19 August 2026. RK-251 remains chemically inactive in healthy tissue and is triggered only inside cancer cells, which typically contain elevated levels of reactive oxygen species (ROS). On detecting high ROS levels, the compound releases a potent anticancer agent called NBDHEX directly inside the tumour cell.
In preclinical laboratory studies, RK-251 showed targeted activity against aggressive triple-negative breast cancer cells while sparing healthy cells, and toxicity studies in zebrafish (Danio rerio) embryos found no obvious signs of toxicity. The findings were published in the Journal of Medicinal Chemistry, a journal of the American Chemical Society; researchers caution that extensive further testing, including human clinical trials, is required before RK-251 could become a treatment option.
GK ByteRK-251 is a "smart" prodrug developed by IASST Guwahati and IIT Guwahati that activates only inside cancer cells via reactive oxygen species (ROS) triggering.On activation, RK-251 releases the anticancer compound NBDHEX selectively inside tumour cells.Tested preclinically against triple-negative breast cancer cells; toxicity screened in zebrafish (Danio rerio) embryos.Findings published in the Journal of Medicinal Chemistry (American Chemical Society); still years from human trials.
Banaras Hindu University (BHU), Varanasi, secured approval for six biomedical research grants worth about ₹15 crore under the Indian Council of Medical Research (ICMR) scheme on 20 August 2026, covering gallbladder cancer detection, antimicrobial resistance, post-kala-azar dermal leishmaniasis (PKDL), paediatric septic shock, and precision oncology for renal cell carcinoma. The work runs through BHU's Institute of Medical Sciences, with support from the Institute of Science and engineering departments, using cohort studies, precision trials and multi-omics biomarker discovery. ICMR, established in 1911, funds the projects under the Department of Health Research, Ministry of Health and Family Welfare.
GK ByteBHU (Varanasi) secured six ICMR-funded biomedical research grants worth ~₹15 crore, approved 20 Aug 2026Research areas: gallbladder cancer detection, antimicrobial resistance (AMR), post-kala-azar dermal leishmaniasis (PKDL), paediatric septic shock, and precision oncology for renal cell carcinomaWork will be led through BHU's Institute of Medical Sciences (IMS), with inputs from the Institute of Science and engineering departmentsICMR functions under the Department of Health Research, Ministry of Health & Family Welfare
The inaugural India-Israel Hackathon concluded on 14 August 2026 with the theme Restorative Healthcare, bringing ~1,300 young innovators from both nations to tackle 14 problem statements in rehabilitation technology. Thapar University (Patiala) was the nodal academic partner and India's Ambassador to Israel J.P. Singh felicitated the winners. Winning ideas included an electricity-free wheelchair-based limb-mobilisation system and an AI-assisted movement-analysis tool, underscoring low-cost frugal health innovation.
GK ByteInaugural India-Israel Hackathon theme: Restorative Healthcare~1,300 innovators; 14 problem statementsThapar University was nodal academic partnerAmbassador J.P. Singh felicitated winners